British American Tobacco PLC (BTI)

From May 8 to today its' up 14%. The Velo nicotine pouches are quite popular and sell well. However, this niche is getting filled with new entrants

come again? Still waiting for those "big sellers"

Charlotte's Web Announces Transaction with BAT: Debenture Conversion and US$10M Equity Investment to Strengthen Balance SheetMarch 30, 2026 10:59 PM
PR Newswire (Canada)

Transaction Addresses Capital Structure and Supports Near-Term Operating Priorities, Including Anticipated CMMI Medicare Pilot Program ParticipationLOUISVILLE, Colo., March 30, 2026 /CNW/ - (TSX: CWEB) (OTCQB: CWBHF) Charlotte's Web Holdings, Inc., a botanical wellness innovation company and the market leader in cannabidiol ("CBD") hemp extract wellness products, today announced a transaction with BT DE Investments, Inc. ("BAT"), a subsidiary of British American Tobacco plc (LSE: BATS and NYSE: BTI), comprising two components: (i) amendment and conversion of BAT's outstanding C$75.3 million principal amount (approximately US$54 million) of the convertible debenture, as well as all accrued interest, into common shares of Charlotte's Web at a conversion price of C$0.94 (approximately US$0.67 at the Bank of Canada exchange rate on March 27, 2026 for estimation purposes); and (ii) a concurrent additional equity investment by BAT of US$10 million by way of a private placement at a price (the "Subscription Price") equal to the greater of (a) C$0.94, or (b) a dollar amount equal to the maximum discount available pursuant to section 607 of the TSX Company Manual applied to the 5-day volume weighted average price of the Company's common shares on the TSX prior to the closing date (collectively, the "Transaction"). Together, the Transaction results in the issuance of approximately 110 million common shares of Charlotte's Web to BAT and represents a total equity commitment of approximately US$75 million. 







Upon completion of the Transaction, approximately US$65 million of total debt will be eliminated from the Company's balance sheet, interest on the debenture will stop accruing, and liquidity will increase for near-term operations.  Charlotte's Web would operate with no long-term debt and with a simplified equity structure.The Company is preparing for anticipated participation in the Centers for Medicare & Medicaid Innovation (CMMI) Medicare pilot program.  In parallel, DeFloria continues to advance its FDA Phase 2 clinical trial program led by Ajna BioSciences. These initiatives require internal investment to optimize execution."In addition to this being an important balance sheet event, it also reflects support for Charlotte's Web and its strategic direction," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "BAT's decision to convert its debenture to equity and invest additional capital removes our largest remaining liability and strengthens our shareholders' equity. The additional US$10 million in new capital reinforces our financial position and provides greater flexibility to participate in the upcoming CMMI Medicare pilot program, subject to receipt of all regulatory approvals. We look forward to seeking shareholder approval to complete this Transaction.""Removing the debenture simplifies our capital structure and avoids approximately US$12 million in future interest, in addition to repayment of the principal," Erika Lind, Chief Financial Officer, stated. "We have worked aggressively over the last two years to reduce and optimize our cost structure. With these changes to our balance sheet and new infusion of capital, we are better positioned to fund near-term priorities."Transaction Rationale The Board of Directors evaluated the Transaction in the context of the Company's current financial position, capital structure, and strategic priorities.Subsequent trading levels have rendered voluntary conversion at the original conversion price unlikely in the near term, which risks leaving a US$67 million liability on the balance sheet and the resulting impact on shareholders' equity value. In the interim, the debenture continues to accrue interest at 5.0% per annum, amounting to approximately US$3 million annually to the Company and up to approximately US$12 million in aggregate interest from June 2026 to the November 2029 debenture maturity date. The Company believes a conversion at C$0.94 is consistent with current market values, and successfully eliminates the Company's largest outstanding liability, removes ongoing interest obligations, and strengthens the balance sheet. Moreover, BAT's concurrent equity investment provides immediate liquidity to support long-term strategic execution. This investment further reinforces the Company's strategic plans to expand its existing medical channel and participate in the CMMI program, subject to regulatory approvals, and underscores BAT's continued support of Charlotte's Web's strategy and leadership.Charlotte's Web shareholders will be asked to approve the Transaction at the annual general and special meeting of the shareholders to be held on or about May 28, 2026. The Company plans to deliver an information circular and proxy statement in connection with the Meeting and will provide additional updates with respect to the Transaction at that time.Transaction OverviewConversion of Outstanding DebentureSubject to shareholder and regulatory approvals, the convertible debenture issued by Charlotte's Web to BAT on November 14, 2022, in the original amount of C$75,341,080 (approximately US$54 million), with an original maturity date of November 14, 2029, will be converted in full into common shares of Charlotte's Web at a conversion price of C$0.94 . The converted amount will include the full principal of C$75,341,080 together with C$14,223,321 (approximately US$10 million) in accrued interest at 5.0% per annum from the original issuance date of November 14, 2022 through the conversion date, for a total converted amount of C$89,564,401 (approximately US$65 million), resulting in the issuance of up to 95,281,277 common shares to BAT. All accrued and unpaid interest will be settled through the issuance of common shares at the C$0.94 conversion price. .US$10 Million Concurrent Private Placement Concurrently with the debenture conversion, BAT will subscribe for an additional non-brokered private placement of up to 14,760,638 common shares of Charlotte's Web at the Subscription Price, for gross proceeds of US$10 million (approximately C$13.9 million). The net proceeds of the cash will be used to support the Company's participation in the anticipated CMMI Medicare pilot program and other permitted purposes if the CMMI program does not proceed.Combined Transaction SummaryIn aggregate, the Transaction results in the issuance of up to approximately 110 million common shares to BAT at the Subscription Price, representing a total equity commitment of approximately C$103.4 million (approximately US$75 million). Following completion, BAT will hold up to approximately 110 million common shares of Charlotte's Web, representing approximately 40% of the Company's then-issued and outstanding common shares on a non-diluted basis, based on 159,683,953 shares currently outstanding and expected to be issued prior to the closing of the Transaction, and up to approximately 270 million shares outstanding immediately following the Transaction.The C$0.94 per share price represents a discount of approximately 5% to the 5-day volume-weighted average price of the Company's common shares on the TSX as of March 27, 2026, for estimation purposes.Investor Rights Agreement On closing of the Transaction, the Company and BAT will enter into an amended and restated investor rights agreement (the "A&R Investor Rights Agreement"), amending and restating the investor rights agreement entered into on November 14, 2022, in connection with the original debenture agreement. The A&R Investor Rights Agreement will provide, among other things, (i) that BAT will have the right to nominate directors in line with its pro rata equity ownership (provided BAT will in any case have the right to nominate at least two directors) for so long as they hold at least 10% of the Company's equity, (ii) for certain restrictions on equity issuances and indebtedness, and (iii) for certain changes to BAT's existing customary top-up rights. Neither the A&R Investor Rights Agreement nor BAT's director nomination rights confer on BAT or any BAT-nominated director any right to direct or control the management or day-to-day operations of the Company, which will continue to be managed by its board and executive management in the ordinary course.Shareholder Approval and Special MeetingCompletion of the Transaction is subject to, among other conditions, TSX approval and shareholder approval. Charlotte's Web shareholders will be asked to approve the Transaction at an annual general and special meeting of the shareholders to be held on or about May 28, 2026.Subject to the receipt of shareholder and TSX approval, the Transaction is expected to close on or about May 28, 2026. Additional Information and Where to Find ItIn connection with the Transaction, Charlotte's Web will file with the SEC a preliminary proxy statement and a definitive proxy statement, each on Schedule 14A and may file other documents with the SEC regarding the Transaction. This release is not a substitute for the proxy statement or any other document that Charlotte's Web may file with the SEC. INVESTORS IN, AND SECURITY HOLDERS OF, CHARLOTTE'S WEB ARE URGED TO READ, WHEN AVAILABLE, THE PRELIMINARY PROXY STATEMENT, THE DEFINITIVE PROXY STATEMENT AND DOCUMENTS INCORPORATED BY REFERENCE THEREIN AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT CHARLOTTE'S WEB AND THE PROPOSED TRANSACTION AND RELATED MATTERS.  When available, the definitive proxy statement and other relevant materials for the Transaction will be mailed or otherwise made available to stockholders of Charlotte's Web as of April 6, 2026.  Investors and security holders may obtain free copies of the proxy statement (when available) and other documents filed with the SEC by Charlotte's Web through the website maintained by the SEC at www.sec.gov or by contacting Charlotte's Web at 700 Tech Court, Louisville, CO 80027 or by telephone at (720) 484-8930.Participants in the SolicitationCharlotte's Web and its directors and executive officers, and other members of management and employees, may be deemed to be participants in the solicitation of proxies in connection with the Transaction under the rules of the SEC. Information regarding the persons who may be deemed participants in the solicitation of proxies in connection with the Transaction will be set forth in the proxy statement when it is filed with the SEC.  You can find more information about Charlotte's Web's directors and executive officers in its Annual Report for the year ended December 31, 2025, on Form 10-K filed with the SEC on [March 31, 2026] and Charlotte's Web's Definitive Annual Meeting Proxy Statement filed with the SEC on April 29, 2025. You may obtain a free copy of these documents as indicated above.Required Early Warning Disclosure Immediately prior to completion of the Transaction, assuming the Convertible Debenture had been converted in full (including all accrued but unpaid interest thereon as of the date hereof) at C$2.00, BAT had the right to acquire beneficial ownership of up to 44,782,800 common shares, subject to a cap of 19.9% of the issued and outstanding common shares (calculated on a non-diluted basis).Immediately after the Transaction, BAT will have beneficial ownership of up to approximately 110 million common shares, representing approximately 40.8% of the issued and outstanding common shares (calculated on a non-diluted basis) based on 269,725,868 common shares that are expected to be issued and outstanding on completion of the Transaction.BAT undertook the Transaction as part of a strategic investment in Charlotte's Web. BAT intends to review its investment in the Company on a continuing basis and may, subject to the terms of the A&R Investor Rights Agreement, depending upon a number of factors, including market and other conditions, increase or decrease its beneficial ownership, control, direction or economic exposure over securities of the Company.An early warning report will be electronically filed with the applicable securities commission in each jurisdiction where the Company is reporting and will be available under the Company's profile on SEDAR+ at www.sedarplus.ca. For further information or to obtain a copy of the early warning report, please contact the Company's representative at the end of this press release.The Company is a corporation existing under the laws of the province of British Columbia with its head office located at 700 Tech Court, Louisville, Colorado 80027, USA. BAT is a corporation existing under the laws of the state of Delaware with its head office located at 401 North Main Street, Winston-Salem, North Carolina 27010, USA.No Offer or SolicitationThis press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transaction. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.About Charlotte's Web Holdings, Inc.Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is a botanical wellness innovation company and market leader in hemp extract wellness. The Company's product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery), CBN gummies, CBG gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online at www.charlottesweb.com.Forward-Looking InformationCertain information provided herein constitutes forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Forward-looking statements are typically identified by words such as "may," "will," "should," "could," "anticipate," "expect," "project," "estimate," "forecast," "plan," "intend," "target," "believe" and similar words suggesting future outcomes or statements regarding an outlook. Forward-looking statements are not guarantees of future performance and readers are cautioned against placing undue reliance on forward-looking statements. Specifically, this press release contains forward-looking statements relating to, but not limited to: completion of the Transaction with BAT, including obtaining the necessary TSX approval and shareholder approval of the Transaction; benefits to the Company of completing the Transaction with BAT; use of proceeds of the Transaction; timing of completion of the Transaction; the Company's participation in the CMMI pilot program; financial impacts to the Company of completing the Transaction; and scheduled timing of the annual general and special meeting of shareholders.By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties, and other factors which may cause actual results, levels of activity, and achievements to differ materially from those expressed or implied by such statements. The forward-looking statements contained in this press release are based on certain assumptions and analysis by management of the Company in light of its experience and perception of historical trends, current conditions and expected future developments and other factors that management believes are appropriate and reasonable. The material factors and assumptions used to develop the forward-looking statements herein include, but are not limited to: the receipt of TSX approval and shareholder approval at the special meeting and the satisfaction of all other conditions to completion of the Transaction; the anticipated timing of the special meeting and Transaction closing; the anticipated impact of the debenture conversion and private placement on the Company's balance sheet, shareholders' equity, and financial position; the intended use of private placement proceeds; expectations around hemp wellness distribution through the CMMI Medicare pilot program; the progress and potential outcomes of DeFloria's Phase 2 clinical trials for AJA001; anticipated cost reductions and their impact on the Company's improving cash flow outlook; regulatory regime changes and federal hemp policy developments; anticipated product development and sales; the success of sales and marketing activities; availability of adequate liquidity and capital to support operations and business plans; and expectations around consumer product demand. In addition, the forward-looking statements are subject to risks and uncertainties pertaining to, among other things: the risk that the Transaction does not receive required shareholder or regulatory approvals or that closing conditions are not satisfied; supply and distribution chains; the market for the Company's products; revenue fluctuations; regulatory changes; loss of customers and retail partners; retention and availability of talent; competing products; share price volatility; loss of proprietary information; product acceptance; internet and system infrastructure functionality; information technology security; available capital to fund operations and business plans; crop risk; economic and political considerations; and including but not limited to those risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ending December 31, 2024, and other risk factors contained in other filings with the Securities and Exchange Commission available at http://www.sec.gov and filings with Canadian securities regulatory authorities available at www.sedarplus.ca. The impact of any one risk, uncertainty, or factor on a particular forward-looking statement is not determinable with certainty as these are interdependent, and the Company's future course of action depends on management's assessment of all information available at the relevant time.Any forward-looking statement in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. Except as required by applicable law, the Company assumes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. All forward-looking statements, whether written or oral, attributable to the Company or persons acting on the Company's behalf, are expressly qualified in their entirety by these cautionary statements.



View original content to download multimedia:https://www.prnewswire.com/news-releases/charlottes-web-announces-transaction-with-bat-debenture-conversion-and-us10m-equity-investment-to-strengthen-balance-sheet-302729362.htmlSOURCE Charlotte's Web Holdings, Inc.

Original: Charlotte's Web Announces Transaction with BAT: Debenture Conversion and US$10M Equity Investment to Strengthen Balance Sheet

Better-for-You Stimulant Formats Gain Scale as Consumer Demand Reshapes Delivery LandscapeMarch 4, 2026 11:51 AM
PR Newswire (Canada)

Issued on behalf of Doseology Sciences Inc.VANCOUVER, BC, March 4, 2026 /CNW/ -- USANewsGroup.com News Commentary — Consumer habits continue to shift, and there's no better example to point at than the rise of pouches. The global oral nicotine pouch market is projected to surge from $5.4 billion in 2024 to over $25 billion by 2030, reflecting a 29.6% CAGR[1]. On top of this, consumer habits are shifting toward tobacco-free formats which are accelerating alongside demand for functional, portable energy delivery systems that eliminate liquid bulk and sugar crashes[2]. This convergence is channeling capital toward consumer goods platforms built around precise dosing, clean ingredients, and modern form factors, creating scalable opportunities for Doseology Sciences (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70), Celsius Holdings (NASDAQ: CELH), British American Tobacco (NYSE: BTI), Turning Point Brands (NYSE: TPB), and Keurig Dr Pepper (NASDAQ: KDP).







Another rising star is functional beverages, a market projected to reach $192.8 billion globally in 2026, driven by wellness trends including cognitive support ingredients and stress-relief botanicals[2]. Energy drinks dominate with 39% market share, benefiting from sustained-release caffeine and natural boosters that appeal to fast-paced consumers seeking alternatives to traditional sugary formats[3].Doseology Sciences (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70) just launched Feed That Brain Energy Pouches in the United States through a direct-to-consumer pilot program, marking the company's first DTC initiative in the U.S. market. Based in Kelowna, British Columbia, Doseology is testing nicotine-free, caffeine-based oral pouches that deliver clean, controlled energy in a discreet format without sugar, smoke, or liquid consumption. The pouches are now available exclusively to U.S. consumers at feedthatbrain.com and Amazon.com.The U.S. pilot represents a key milestone in Doseology's strategy to validate oral pouch delivery as a scalable stimulant platform, beginning with non-nicotine energy products. The company will use this phase to evaluate consumer adoption, usage frequency, and repeat purchase behavior, with particular focus on underserved demographics seeking alternatives to traditional energy drinks."This U.S. pilot is a disciplined and deliberate step in Doseology's strategy to build a scalable oral stimulant platform," said Larry Latowsky, Executive Chairman of Doseology. "Feed That Brain demonstrates how controlled, non-nicotine energy delivery can meet evolving consumer preferences while generating the operational insight required for responsible growth."Feed That Brain Energy Pouches are designed for modern, on-the-go use, offering consumers clarity and control without the volatility commonly associated with liquid energy formats. The product reflects Doseology's broader focus on precision dosing, predictability, and experience-led design.The company also recently appointed Larry Latowsky as Executive Chairman, bringing experience from his tenure as President and CEO of Katz Group Canada, which operated over 1,500 pharmacy locations. Latowsky cited the clarity of Doseology's strategy and team quality as reasons for joining, stating confidence in building a durable platform and unlocking significant long-term value.Doseology also recently granted 140,000 restricted share units and 210,000 performance share units to a director, with RSUs vesting in equal monthly increments over 36 months and PSUs vesting upon achievement of defined performance milestones.CONTINUED… Read this and more news for Doseology Sciences at: https://usanewsgroup.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/In other industry developments:Celsius Holdings (NASDAQ: CELH) recently reported full-year 2025 revenue of $2.5 billion, an 86% increase driven by portfolio integration across CELSIUS, Alani Nu, and Rockstar Energy brands. The company achieved approximately 20% dollar share of the U.S. energy drink category in Q4 2025 while generating adjusted EBITDA of $619.6 million, representing 142% growth year-over-year."2025 was a defining year for Celsius Holdings as we delivered record full-year revenue of $2.5 billion, underscoring the power of our brands and the strength of our growth model," said John Fieldly, Chairman and CEO of Celsius Holdings. "With CELSIUS, Alani Nu, and Rockstar Energy, we're building a scaled Modern Energy portfolio with distinct roles, recruiting new consumers and expanding consumption occasions."As PepsiCo's energy category captain in the U.S., Celsius achieved 99.5% all-commodity volume distribution across U.S. tracked channels while increasing total distribution points by 15%. Alani Nu retail sales increased 101% year-over-year, continuing category outperformance driven by strong innovation and adoption by new consumers.British American Tobacco (NYSE: BTI) recently presented at the 2026 CAGNY Conference, reaffirming full-year 2026 guidance indicating performance at the lower end of constant-currency ranges. The company's smokeless brands—Vuse, glo, and Velo—reached over 31 million adult consumers worldwide as of December 31, 2025, with smokeless products accounting for 18.2% of group revenue. BAT aims to reach 50 million consumers with smokeless products by 2030 and targets 50% of group revenue from these products by 2035.The company's Velo nicotine pouch brand continues expanding globally, with recent regulatory approvals in key markets supporting distribution growth. In Kenya, BAT resumed Velo sales in July 2025 following regulatory clarity, projecting the product will contribute 15-25% of revenue in the medium term as the company transitions its portfolio toward non-combustible alternatives.Turning Point Brands (NYSE: TPB) announced fourth quarter and full-year 2025 results, with Modern Oral segment net sales increasing 266% to $41.3 million in Q4, accounting for 34% of total company net sales compared to 12% in the prior year. Total consolidated net sales increased 29.2% to $121.0 million for the quarter, while full-year 2025 net sales rose 28.4% to $463.1 million driven by triple-digit growth in Modern Oral sales."We are excited by the growth of the modern oral category and the strong performance of our FRE and ALP brands," said Graham Purdy, President and CEO of Turning Point Brands. "We are well positioned to achieve double-digit share of the category over time, while our legacy brands continue to generate durable cash flows that provide strong funding for investment in future growth."For 2026, the company expects Modern Oral gross revenue of $220-$240 million and net revenue of $180-$190 million. Fourth quarter adjusted EBITDA increased 14% to $30.0 million, with Turning Point ending the quarter with total liquidity of $290.1 million and plans to expand distribution for its ALP brand into brick-and-mortar retail in Q2 2026.Keurig Dr Pepper (NASDAQ: KDP) recently announced a 2026 lineup of more than 35 new beverage varieties across its carbonated soft drinks, teas, waters, energy, and juice portfolios, building on 2025 innovations that included the top CSD launch of the year. The company is entering 2026 with flavor leadership positioning, offering all new CSD innovations in both regular and zero-sugar options as zero-sugar beverages drive 6x more dollar growth than regular varieties."Consumers want beverages that fit every need throughout their day, and our 2026 lineup does exactly that while offering even more ways to enjoy the brands they love," said Katie Webb, VP of Innovation at Keurig Dr Pepper. "Our State of Beverages 2025 Trend Report uncovered that 44% of Americans, and an impressive 72% of Gen Z, try new beverages each month, underscoring the tremendous opportunity for flavor exploration and fan-driven innovation."The innovation slate includes the return of fan-favorite Dr Pepper Creamy Coconut in April, new Canada Dry Fruit Splash Strawberry rolling out nationally, and expanded energy offerings across GHOST, C4, and Bloom brands. Keurig Dr Pepper reported full-year 2025 net sales of $10.4 billion with 11.9% growth, while targeting 2026 net sales of $25.9-$26.4 billion with low-double-digit adjusted EPS growth.Article Source: https://usanewsgroup.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/CONTACT:USANEWSGROUPinfo @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USANewsGroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). "). This article is being distributed for Maynard Communications ("MAY"), who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Doseology Sciences. Inc. advertising or digital media, but expects to be paid a fee from ("MAY"). There may be 3rd parties who may have shares of Doseology Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Doseology Sciences Inc., which were purchased as a part of a private placement. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Doseology Sciences Inc.; this is a paid advertisement, we currently own shares of Doseology Sciences Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.grandviewresearch.com/press-release/global-nicotine-pouches-markethttps://www.openpr.com/news/4408369/functional-beverage-market-forecast-2026-2036-globalhttps://www.zionmarketresearch.com/report/functional-drinks-marketLogo - https://mma.prnewswire.com/media/2838876/5836617/USA_News_Group_Logo.jpg



View original content to download multimedia:https://www.prnewswire.com/news-releases/better-for-you-stimulant-formats-gain-scale-as-consumer-demand-reshapes-delivery-landscape-302704191.html

Original: Better-for-You Stimulant Formats Gain Scale as Consumer Demand Reshapes Delivery Landscape

These are the big sellers here. Check any 7/11
https://www.velo.com/us

try again

Updated Earnings Guidance:

https://www.nasdaq.com/articles/british-american-tobacco-h1-revenue-slightly-ahead-guidance-updates-fy-revenue-growth

no. 7-11 has

Has the market finally came to appreciate this cheap PE dividend payer? Really can't go wrong on tabbacco

Don’t overlook this undervalued synergy!

British American Tobacco already has existing deals with both Charlottes Web Holdings $CWBHF and Organigram Holdings $OGI… There are a few possibilities for how BAT could leverage its partnerships with both companies:

Joint Investment: BAT, Charlottes Web, and Organigram could collaborate on a joint venture or even a merger (depending on regulations) to create a larger cannabis and CBD company. This would require significant planning and navigating potential regulatory hurdles.”

Market Expansion: BATs global reach could be valuable for both Charlottes Web and Organigram. BAT could help them enter new markets where cannabis or CBD products are legal. For example, BAT might leverage its existing distribution channels for these products.

Knowledge Sharing: BAT could act as a bridge between the two companies, facilitating knowledge sharing and best practices in areas like marketing, regulatory compliance, and cultivation techniques.

this is trading cheap Yeah tobacco isn't the hot thing to invest in but it makes money and lots of it

Easy buy here indeed

"British American Tobacco : BAT invests in Charlotte's Web, a leading US producer of hemp extract wellness products":
11/14/2022 | 06:11pm EST
https://www.marketscreener.com/quote/stock/BRITISH-AMERICAN-TOBACCO-4001163/news/British-American-Tobacco-BAT-invests-in-Charlotte-s-Web-a-leading-US-producer-of-hemp-extract-wel-42312972/

"BAT invests in Charlotte’s Web, a leading US producer of hemp extract wellness products":
14 November 2022
https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOCL6PSP#

FYI...$BTI+$CWBHF...
Effective as of November 14, 2022, we entered into a subscription agreement with BT DE Investments, Inc. a wholly-owned subsidiary of BAT Group (LSE: BATS and NYSE: BTI), providing for the issuance of an approximately $56.8 million convertible debenture (the “Debenture”) is convertible into 19.9% ownership of the Company’s common shares at a conversion price of C$2.00 per common share of the Company on the Toronto Stock Exchange (TSX). The Debenture will accrue interest at an annualized rate of 5% until such time that there is federal regulation permitting the use of CBD as an ingredient in food products and dietary supplements in the United States. Following federal regulation of CBD, the annualized rate of interest shall reduce to 1.5%. The maturity date for the Debenture shall be November 2029. The Subscription Agreement contains customary representations and warranties and covenants. The funds from this Debenture can be used for operating purposes to fund the Company, as approved by the board of directors or in accordance with the Company’s board-approved budget.
https://www.otcmarkets.com/filing/html?id=16201884&guid=Ly_-kFBCz96Iyih

looks like people are being smart and putting there money in these type of stocks low PE and healthy dividend and cigarettes are bought in any economy lol

BTI raising back up up 10% here

“British American Tobacco (BAT), the world’s No. 2 tobacco company, on Wednesday warned of steeper declines in cigarette sales globally mainly due to waning demand in its main U.S. market, sending its shares lower.”

https://www.reuters.com/article/us-brit-am-tobacco-outlook/bat-warns-of-steeper-declines-in-cigarette-sales-shares-slip-idUSKCN1TD0NH

Short here with Brexit uncertainty and bearish parSAR on the inverted technical pincher chart. GL!

https://stockcharts.com/h-sc/ui?s=BTI&p=D&yr=0&mn=7&dy=0&id=p42191071415

Vuse will take over the vaping market. Ready to enter here soon. Juul (aka Phillip Morris) is done for.

BTI SHOULD take over this little known Canadian company ABCANN. Deal or no deal.

Don't miss our Group Scientific and R&D Director, Dr David O'Reilly, as the closing keynote speech at this years #GTNF at 17:40 EST pic.twitter.com/jXuEG3YWgr— Omni™ (@smokelessworld) September 14, 2017

http://blumartini.com/22nd-century-group-inc-extreme-growth-potential-and-takeover-target-interview-with-the-ceo/

Just because I wrote it and it's a great read. Go register while you're there!

https://www.nytimes.com/reuters/2017/08/31/business/31reuters-brit-am-tobacco-moves.html

BTI and XXII gonna cut a deal? Should find out in less than a month

Agreed. Both XXII and BTI should take off soon

We are going to find out very soon. XXII and BAT could find themselves at the forefront of something amazing in the industry

I would think it's gonna pick up soon here. Both tickers should benefit if things play out

We will find out soon enough and NLT 10.1

Time and time again tobacco shows us the incredible long term potential it has. So long as the government refrains from prohibition people will pay a reasonable tax to buy the smoke they love. MONEY FOR ALL AROUND.

The RAI merge was incredible making this IMO the greatest tobacco conglomerate around.

I LOVE tobacco stocks but especially THIS one.

This will be worth $150+ per share in 5 years easy.

Incredible potential here

XXII AND BTI TOGETHER HAND IN HAND

Well wrong board? Doesn't matter,hopefully research will make a a life changing outcome for all .

??? Is this part of the same research?
http://www.ctvnews.ca/health/canadian-researchers-break-blood-brain-barrier-with-new-ultrasound-treatment-1.2648878

Bioasis board?

Very smart move on the part of both BAT & XXII to sign an agreement to advance the two companies utilizing XXII's proprietary properties. Great things to come for those vested in both. Below from the N/R by both BAT & XXII

“This partnership with British American Tobacco, which sells product in approximately 180 countries, represents 22nd Century’s greatest growth milestone to date and an important step in the development of 22nd Century’s next generation tobacco products. BAT has always been our first choice as a partner,” stated Joseph Pandolfino, 22nd Century’s Founder and Chief Executive Officer.

Gary Nicholson, BAT’s Head of Global Leaf Research, stated that “BAT is excited to be working with 22nd Century in this area of developing technology. This work is part of BAT’s ongoing Research & Development activities relating to tobacco products.”

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering or plant breeding. 22nd Century owns or is the exclusive licensee of 112 issued patents in 78 countries plus an additional 38 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial tobacco products and tobacco harm reduction products in development. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.

Why no chatter on this board..... XXII......Deal?